LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 19 of 497
Next
>>
>
451 to 475 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	CP724714	0.12	uM	LJP5	1	A11	72	hr	1657	5202	5505	0.9448	0.9211
BT-20	CP724714	0.12	uM	LJP5	2	A11	72	hr	1657	4973	5505	0.9033	0.8616
BT-20	CP724714	0.12	uM	LJP5	3	A11	72	hr	1657	5060	5505	0.9191	0.8842
BT-20	CP466722	0.12	uM	LJP5	1	I11	72	hr	1657	5795	5505	1.0526	1.0752
BT-20	CP466722	0.12	uM	LJP5	2	I11	72	hr	1657	5187	5505	0.9421	0.9172
BT-20	CP466722	0.12	uM	LJP5	3	I11	72	hr	1657	5745	5505	1.0435	1.0622
BT-20	Crizotinib	0.12	uM	LJP5	1	A23	72	hr	1657	5161	5505	0.9374	0.9104
BT-20	Crizotinib	0.12	uM	LJP5	2	A23	72	hr	1657	5067	5505	0.9203	0.8860
BT-20	Crizotinib	0.12	uM	LJP5	3	A23	72	hr	1657	4874	5505	0.8853	0.8358
BT-20	Momelotinib	0.12	uM	LJP5	1	P11	72	hr	1657	4871	5505	0.8847	0.8351
BT-20	Momelotinib	0.12	uM	LJP5	2	P11	72	hr	1657	4816	5505	0.8747	0.8208
BT-20	Momelotinib	0.12	uM	LJP5	3	P11	72	hr	1657	4621	5505	0.8393	0.7701
BT-20	Dasatinib	0.12	uM	LJP5	1	D05	72	hr	1657	3441	5505	0.6250	0.4634
BT-20	Dasatinib	0.12	uM	LJP5	2	D05	72	hr	1657	3141	5505	0.5705	0.3855
BT-20	Dasatinib	0.12	uM	LJP5	3	D05	72	hr	1657	3919	5505	0.7119	0.5878
BT-20	Dasatinib	0.12	uM	LJP6	1	I05	72	hr	1657	1938	5505	0.3520	0.0728
BT-20	Dasatinib	0.12	uM	LJP6	2	I05	72	hr	1657	1747	5505	0.3173	0.0232
BT-20	Dasatinib	0.12	uM	LJP6	3	I05	72	hr	1657	1816	5505	0.3298	0.0411
BT-20	Dovitinib	0.12	uM	LJP5	1	E23	72	hr	1657	4519	5505	0.8208	0.7436
BT-20	Dovitinib	0.12	uM	LJP5	2	E23	72	hr	1657	3756	5505	0.6822	0.5453
BT-20	Dovitinib	0.12	uM	LJP5	3	E23	72	hr	1657	3803	5505	0.6907	0.5575
BT-20	Enzastaurin	0.12	uM	LJP5	1	D17	72	hr	1657	5784	5505	1.0506	1.0723
BT-20	Enzastaurin	0.12	uM	LJP5	2	D17	72	hr	1657	5736	5505	1.0418	1.0599
BT-20	Enzastaurin	0.12	uM	LJP5	3	D17	72	hr	1657	6293	5505	1.1430	1.2046
BT-20	Erlotinib	0.12	uM	LJP5	1	M23	72	hr	1657	5077	5505	0.9221	0.8886

|<
<<
Previous
Page 19 of 497
Next
>>
>
451 to 475 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)